The FDA hurts. Lester Crawford, the recently resigned commissioner, left after serving only a year, and now the Dr. Andrew von Eschenbach is coming under criticism because he will be serving simultaneously as head of the National Cancer Institute and as the acting FDA commissioner. Can he do both? Will be be able to run an organization that presides over umpteen gagillion NCI-sponsored trials by simply recusing himself? Will the President call in Haliburton to approve cancer trials? Tune in at 11.
Update: Never mind, a reader tells us.